Drug Manufacturing Innovation Center to Transform UK Pharma

The construction of a new center for innovation in drug manufacturing that will solve the main challenges of the pharmaceutical industry and accelerate access to affordable drugs has reached a climax.

Located in Renfrewshire, at the heart of the new Advanced Manufacturing Innovation District Scotland (AMIDS), the £ 35million Medicines Manufacturing Innovation Center is poised to develop next-generation pharmaceutical manufacturing processes to advance innovation in the supply chain. supply of drugs.

The facility was developed through a public-private collaboration between the technology innovation organization, CPI, University of Strathclyde, UK Research and Innovation, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.

Supply Chain

Innovation in new medicines and the pharmaceutical supply chain is essential to adapt to the changing needs of global populations and to drive a healthier society. The environmental and financial implications of pharmaceutical manufacturing can hamper the ability to effectively respond to global health challenges and to streamline the supply of drugs to patients.

With collaboration at the heart of its mission, the new innovation facility will help solve these pharmaceutical challenges by providing cutting-edge technologies as well as expertise in sustainable business growth. Industry, academia, healthcare providers and regulators will work collaboratively in a GMP environment to drive new technologies and provide a clear path for their adoption into the pharmaceutical supply chain. A cleanroom suite will help users develop processes using Industry 4.0 manufacturing technologies, including continuous, digital and stand-alone manufacturing.

Operating on a commercial scale, the facility will industrialize new patient-centered drug production techniques, including real-time drug delivery and integrated process analysis. Technologies will transform manufacturing processes, support reduction of materials used in process development, and accelerate lead times to achieve the right manufacturing principles for the first time and in real time.

After completion of the works, the internal layout of the facility will be completed in early 2022. In the first 5 years of its operation, the center is expected to support more than 100 jobs, both technical and non-technical, and generate a £ 200million investment in advanced technologies. technologies. The facility aims to become an international flagship in drug manufacturing, boost international engagement and attract companies that are not currently present in the UK.

Starting in early 2022, companies of all sizes will be able to tour the facility and engage in discussions about accessing transformative technology and participating in ambitious collaborative projects to develop new pharmaceutical innovations.

The Center was built by Tilbury Douglas, with support from architects Baker Hicks.

Increase momentum

Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Center, Quality and Biologics, at CPI, said: “The Medicines Manufacturing Innovation Center will help the pharmaceutical industry accelerate technology translation by building partnerships, working with regulators and ‘associating with innovators. This will ultimately lead to reduced time to market, increased productivity, improved compliance and reduced carbon footprint of drug manufacturing. Ahead of the center’s full completion in early 2022, we continue to work with industry and academic partners to develop next-generation digital manufacturing technologies, bringing us closer to drug innovation that will ultimately benefit patients. . “

Dr Clive Badman, Professor of Practice at the University of Strathclyde, said: “It is extremely exciting to see the Medicines Manufacturing Innovation Center take shape and reach this important milestone in its development. As a strategic partner, we look forward to applying our cutting-edge research, innovation and expertise in the manufacture of cutting-edge medicines to help address some of the greatest health challenges facing the world today.

“By working with our industry partners, the Medicines Manufacturing Innovation Center will help transform the way medicines are manufactured, enhance security of supply and create jobs and economic benefits for Glasgow, Scotland and beyond. “

Jon-Paul Sherlock, Senior Director of Innovative Manufacturing Technologies at AstraZeneca, said: “Patients and healthcare systems expect rapid, robust and cost-effective development and delivery of future drugs. These drugs are becoming more and more complex to manufacture, so we must innovate and push the boundaries of science and manufacturing technology. The Medicines Manufacturing Innovation Center will foster collaboration between industry, academia, equipment suppliers and regulators to reduce risk and accelerate the implementation of new transformational manufacturing technologies. “

Andy Jones, ISCF Medicines Manufacturing Challenge Director at Innovate UK, said: “The Medicines Manufacturing Innovation Center will help place the UK at the heart of the global life science economy, particularly for non-biological therapies such as small molecules and oligonucleotides. It will focus on speed, flexibility and efficiency in drug manufacturing and will not only help the UK meet the health challenges of a diverse and aging population, but will make it a great place for investment. and innovation in life sciences.

Excellent asset

Paul Foley, Senior Project Manager at Scottish Enterprise, said: “It’s fantastic to see the structure of the building completed and getting closer to its full opening next year. At Scottish Enterprise we are proud to have contributed £ 15million in funding alongside our industry expertise to help create a great asset for the pharmaceutical industry in Scotland and the UK, the center providing a platform for companies to collaborate, innovate and develop cutting-edge processes. and technologies for the benefit of patients.

Cameron Stewart, Regional Manager for Tilbury Douglas, said: “Today marks a real construction milestone for the project and our team is eager to return the center to completion. We are proud to work alongside the partners involved and, together with our supply chain, we are working hard to provide a high quality and highly technical center that will include laboratories, ISO 8 pharmaceutical clean rooms and support activities in accordance with BPF. We are delighted to be involved in a project that will make such a difference for the pharmaceutical industry. “

Renfrewshire Council Chief Iain Nicolson said: “It is great to see the excellent progress being made in building the Medicines Manufacturing Innovation Center here in Renfrewshire, in the Advanced Manufacturing Innovation District Scotland (AMIDS).

“I am excited about its potential to transform drug manufacturing, while creating clean, green ways of working and supporting a healthier society. I am sure the completed center will enjoy its headquarters at AMIDS, the Scottish headquarters of manufacturing innovation, providing a unique environment for collaboration and innovation that attracts cutting-edge companies to locate here, bringing with them jobs. and fantastic opportunities.

Source link

Comments are closed.